Skip to main content

Table 5 Comparison of clinical response between ANA titer increased and no-change patients

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

 

ANA after IFX

 

EULAR

Increased

No change

P value a

response

(n = 13)

(n = 76)

 

Good

8%

54%

0.001

(Remission)

(0)

(42%)

0.001

Moderate

15%

20%

0.001

No

77%

26%

0.001

  1. ANAs, antinuclear antibodies; IFX, infliximab.
  2. aAnalyzed with χ2 test.